OrthoTrophix Presents Data on TPX-100, Meniscal Pathology and Structural Progression in Knee Osteoarthritis
Two studies at ACR Convergence 2026 suggest potential structural effects of TPX-100 and identify patients who may benefit most. FOSTER CITY, Calif., Nov. 9, 2026 /PRNewswire/ -- OrthoTrophix, Inc., a privately held biopharmaceutical company, today announced data from two posters at ACR...